The DOI matches its Crossref record.
Enzyme replacement therapy in late‐onset Pompe's disease: A three‐year follow‐up
Abstract
Pompe's disease is an autosomal recessive myopathy. The characteristic lysosomal storage of glycogen is caused by acid α‐glucosidase deficiency. Patients with late‐onset Pompe's disease present with progressive muscle weakness also affecting pulmonary function. In search of a treatment, we investigated the feasibility of enzyme replacement therapy with recombinant human α‐glucosidase from rabbit milk. Three patients (aged 11, 16, and 32 years) were enrolled in the study. They were all wheelchair‐bound and two of them were ventilator dependent with a history of deteriorating pulmonary function. After 3 years of treatment with weekly infusions of α‐glucosidase, the patients had stabilized pulmonary function and reported less fatigue. The youngest and least affected patient showed an impressive improvement of skeletal muscle strength and function. After 72 weeks of treatment, he could walk without support and finally abandoned his wheelchair. Our findings demonstrate that recombinant human α‐glucosidase from rabbit milk has a therapeutic effect in late‐onset Pompe's disease. There is good reason to continue the development of enzyme replacement therapy for Pompe's disease and to explore further the production of human therapeutic proteins in the milk of mammals. Ann Neurol 2004;55:000–000
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Delivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597
The natural course of non–classic Pompe’s disease; a review of 225 published cases
Winkel, L. P. F., Hagemans, M. L. C., Doorn, P. A., Loonen, M. C. B., Hop, W. J. C., Reuser, A. J. J., & Ploeg, A. T. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0922-9 · Cited by 344
Self-citationvan der Meijden, J. C., Kruijshaar, M. E., Harlaar, L., Rizopoulos, D., van der Beek, N. A. M. E., & van der Ploeg, A. T. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0166-3 · Cited by 37
“Supplemental Table 2 summarizes the results of eight publications that report on the outcomes of children treated with ERT (Winkel et al 2004; Rossi et al 2007; van Capelle et al 2008; Bembi et al 2010; van Capelle et al 2010; Ishigaki et al 2012; Deroma et al 2014; Porta et al 2015).”
BackgroundMethodInfluential
Metadata
- Authors
- Winkel, L. P. F., Van den Hout, J. M. P., Kamphoven, J. H. J., Disseldorp, J. A. M., Remmerswaal, M., Arts, W. F. M., Loonen, M. C. B., Vulto, A. G., Van Doorn, P. A., De Jong, G., Hop, W., Smit, G. P. A., Shapira, S. K., Boer, M. A., Reuser, A. J. J., Van der Ploeg, A. T., & van Diggelen, O. P.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2004-03-21
- Volume
- 55
- Issue
- 4
- Pages
- 495-502
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2001805850
- Cited by
- 233
- References
- 0
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enzyme replacement therapy in late‐onset Pompe's disease: A three‐year follow‐up. https://app.cochat.ai/papers/10.1002/ana.20019
- The paper
- Winkel, L. P. F., Van den Hout, J. M. P., Kamphoven, J. H. J., Disseldorp, J. A. M., Remmerswaal, M., Arts, W. F. M., Loonen, M. C. B., Vulto, A. G., Van Doorn, P. A., De Jong, G., Hop, W., Smit, G. P. A., Shapira, S. K., Boer, M. A., Reuser, A. J. J., Van der Ploeg, A. T., & van Diggelen, O. P. (2004). Enzyme replacement therapy in late‐onset Pompe's disease: A three‐year follow‐up. Annals of Neurology. https://doi.org/10.1002/ana.20019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
